Neurology & Brain Disorders Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

REVERSE-Long COVID-19 With Baricitinib Study

This phase 3 trial led by Vanderbilt University Medical Center is testing baricitinib, a pill that may help adults experiencing brain fog or heart and lung symptoms after COVID-19. Although the study is currently withdrawn, if restarted and successful, it might offer a new way to improve thinking and breathing problems caused by Long COVID. This research reflects ongoing efforts to find treatments for the lasting effects many face after recovering from COVID-19.

Preventing Alzheimer's With Cognitive Training

The University of South Florida is conducting a large phase 3 study to see if a special brain training program can delay memory loss and dementia in older adults. This program does not involve medication and aims to help people keep their thinking skills sharp for longer. Since it is recruiting participants across seven locations in the United States, it may provide new options for those wanting to maintain mental function as they age.

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

This global phase 3 trial by Eli Lilly is testing donanemab, a drug designed to slow down the progression of early Alzheimer’s disease. Results so far show ongoing follow-up to understand how well the treatment works and its safety. If proven effective, donanemab could give people diagnosed early with Alzheimer’s a new option to help preserve their memory and thinking abilities for a longer time.

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

This completed phase 3 study evaluated solanezumab, an antibody treatment targeting brain changes linked to Alzheimer’s, in older adults who may be at risk of memory problems. By focusing on early intervention before symptoms become severe, it aimed to slow cognitive decline. The trial involved over 1100 participants worldwide, contributing valuable information about potential ways to delay memory loss.

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN-TU)

Washington University School of Medicine is running this phase 2 trial to test new investigational drugs for people with a genetic form of early onset Alzheimer’s disease. The goal is to see if these treatments can slow dementia symptoms and change disease markers. Although the study is currently active but not recruiting, it represents hope for families affected by inherited Alzheimer’s to find therapies beyond what is currently available.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.